{"id":68058,"date":"2026-06-12T14:34:27","date_gmt":"2026-06-12T06:34:27","guid":{"rendered":"https:\/\/flcube.com\/?p=68058"},"modified":"2026-06-12T14:34:28","modified_gmt":"2026-06-12T06:34:28","slug":"hj-science-launches-hk1-11-billion-ipo-on-hong-kong-exchange-to-advance-clinical-stage-pipeline-in-autoimmune-metabolic-and-oncology-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68058","title":{"rendered":"HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>HJ Science Co., Ltd.<\/strong>, (HKG: 6132) a China-based clinical-stage biotechnology company, announced its <strong>proposed initial public offering (IPO)<\/strong> on the <strong>Hong Kong Stock Exchange<\/strong>, with a <strong>global offering of 13,600,000 H shares<\/strong> at an <strong>offer price of HKD81.80 (USD 10.43) per share<\/strong>, raising approximately <strong>HK$1.11 billion (USD 142 million)<\/strong> in gross proceeds.<\/p>\n\n\n\n<h2 id=\"h-ipo-details\" class=\"wp-block-heading\">IPO Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Exchange<\/strong><\/td><td>Hong Kong Stock Exchange<\/td><\/tr><tr><td><strong>Shares Offered<\/strong><\/td><td>13,600,000 H shares<\/td><\/tr><tr><td><strong>Offer Price<\/strong><\/td><td>HKD81.80 (USD 10.43) per share<\/td><\/tr><tr><td><strong>Gross Proceeds<\/strong><\/td><td>HKD1.11 billion (USD 142 million)<\/td><\/tr><tr><td><strong>Company Founded<\/strong><\/td><td>2017<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Clinical-stage biotechnology company<\/td><\/tr><tr><td><strong>Therapeutic Areas<\/strong><\/td><td>Autoimmune, metabolic, and oncological diseases<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-core-pipeline-overview\" class=\"wp-block-heading\">Core Pipeline Overview<\/h2>\n\n\n\n<h3 id=\"h-lead-candidates-class-1-innovative-small-molecule-drugs\" class=\"wp-block-heading\">Lead Candidates \u2013 Class 1 Innovative Small-Molecule Drugs<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Mechanism<\/th><th>Indications<\/th><th>Development Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>HJ787<\/strong><\/td><td>Selective TYK2 inhibitor<\/td><td>Mild-to-moderate atopic dermatitis, mild-to-moderate acne vulgaris, neurodermatitis, psoriasis<\/td><td>Clinical-stage<\/td><\/tr><tr><td><strong>HJ178<\/strong><\/td><td>Dual GLP-1\/GIP receptor agonist (oral)<\/td><td>Type 2 diabetes, overweight\/obesity<\/td><td>Clinical-stage<\/td><\/tr><tr><td><strong>HJ891<\/strong><\/td><td>Oral KRAS G12C inhibitor<\/td><td>Second-line monotherapy for KRAS G12C-mutated NSCLC; first-line combination therapy for non-squamous NSCLC with KRAS G12C mutation<\/td><td>Clinical-stage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-additional-pipeline-assets\" class=\"wp-block-heading\">Additional Pipeline Assets<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical-stage candidate:<\/strong> HJ197<\/li>\n\n\n\n<li><strong>Preclinical candidates:<\/strong> HJ356, HJ093, HJ199, HJ198, HJ086<\/li>\n\n\n\n<li><strong>Total pipeline:<\/strong> 9 drug candidates across multiple therapeutic areas<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-drug-profile-amp-strategic-differentiation\" class=\"wp-block-heading\">Drug Profile &amp; Strategic Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Strength:<\/strong> All three core products are <strong>Class 1 innovative small-molecule drugs developed in-house<\/strong>, demonstrating strong internal R&amp;D capabilities<\/li>\n\n\n\n<li><strong>TYK2 Innovation:<\/strong> HJ787 targets the emerging <strong>TYK2 pathway<\/strong> in autoimmune diseases, competing with recently approved therapies like deucravacitinib<\/li>\n\n\n\n<li><strong>Oral Peptide Mimetics:<\/strong> HJ178 represents the competitive <strong>oral GLP-1\/GIP dual agonist<\/strong> space, challenging injectable competitors in the obesity\/diabetes market<\/li>\n\n\n\n<li><strong>KRAS Targeting:<\/strong> HJ891 addresses the <strong>KRAS G12C mutation<\/strong>, a validated but challenging oncology target with recent breakthrough approvals<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-investment-thesis\" class=\"wp-block-heading\">Market Context &amp; Investment Thesis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Area<\/th><th>Market Opportunity<\/th><th>Competitive Landscape<\/th><th>HJ Science Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Autoimmune<\/strong><\/td><td>Global TYK2 inhibitors market projected to reach USD 5+ billion by 2030<\/td><td>BMS leads with Sotyktu; multiple competitors in development<\/td><td>Differentiated TYK2 inhibitor with broad indication potential<\/td><\/tr><tr><td><strong>Metabolic<\/strong><\/td><td>GLP-1 market expected to exceed USD 100 billion by 2030<\/td><td>Novo Nordisk and Lilly dominate with injectables; oral formulations emerging<\/td><td>Oral dual GLP-1\/GIP agonist targeting both diabetes and obesity<\/td><\/tr><tr><td><strong>Oncology<\/strong><\/td><td>KRAS G12C inhibitors market estimated at USD 2-3 billion annually<\/td><td>Amgen, Mirati, and others have approved KRAS G12C inhibitors<\/td><td>Oral formulation with combination therapy strategy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The IPO proceeds will support the advancement of HJ Science&#8217;s diversified pipeline through pivotal clinical trials and regulatory submissions, while strengthening its position as an integrated biotechnology company with capabilities across multiple high-value therapeutic areas.<\/p>\n\n\n\n<h2 id=\"h-strategic-outlook\" class=\"wp-block-heading\">Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Geographic Strategy:<\/strong> Hong Kong listing provides access to both international and Greater China capital markets<\/li>\n\n\n\n<li><strong>Pipeline Diversification:<\/strong> Balanced portfolio across three major therapeutic areas reduces development risk<\/li>\n\n\n\n<li><strong>Innovation Focus:<\/strong> All lead candidates represent novel approaches with first-in-class or best-in-class potential<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Each lead program addresses markets with significant unmet medical needs and substantial commercial opportunities<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding IPO completion, clinical development timelines, regulatory pathways, and commercial potential. Actual results may differ due to risks including market conditions, regulatory approvals, clinical trial outcomes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061200084_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026061200084_c.\"><\/object><a id=\"wp-block-file--media-f69a074d-388e-403a-b964-78f83c3edd1f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061200084_c.pdf\">2026061200084_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061200084_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f69a074d-388e-403a-b964-78f83c3edd1f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HJ Science Co., Ltd., (HKG: 6132) a China-based clinical-stage biotechnology company, announced its proposed initial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68063,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4794,72],"class_list":["post-68058","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hj-science","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HJ Science Co., Ltd., (HKG: 6132) a China-based clinical-stage biotechnology company, announced its proposed initial public offering (IPO) on the Hong Kong Stock Exchange, with a global offering of 13,600,000 H shares at an offer price of HKD81.80 (USD 10.43) per share, raising approximately HK$1.11 billion (USD 142 million) in gross proceeds.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68058\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies\" \/>\n<meta property=\"og:description\" content=\"HJ Science Co., Ltd., (HKG: 6132) a China-based clinical-stage biotechnology company, announced its proposed initial public offering (IPO) on the Hong Kong Stock Exchange, with a global offering of 13,600,000 H shares at an offer price of HKD81.80 (USD 10.43) per share, raising approximately HK$1.11 billion (USD 142 million) in gross proceeds.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68058\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-12T06:34:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-12T06:34:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1202.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68058#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68058\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies\",\"datePublished\":\"2026-06-12T06:34:27+00:00\",\"dateModified\":\"2026-06-12T06:34:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68058\"},\"wordCount\":508,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68058#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1202.webp\",\"keywords\":[\"HJ Science\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68058#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68058\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68058\",\"name\":\"HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68058#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68058#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1202.webp\",\"datePublished\":\"2026-06-12T06:34:27+00:00\",\"dateModified\":\"2026-06-12T06:34:28+00:00\",\"description\":\"HJ Science Co., Ltd., (HKG: 6132) a China-based clinical-stage biotechnology company, announced its proposed initial public offering (IPO) on the Hong Kong Stock Exchange, with a global offering of 13,600,000 H shares at an offer price of HKD81.80 (USD 10.43) per share, raising approximately HK$1.11 billion (USD 142 million) in gross proceeds.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68058#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68058\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68058#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1202.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1202.webp\",\"width\":1080,\"height\":608,\"caption\":\"HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68058#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies - Insight, China&#039;s Pharmaceutical Industry","description":"HJ Science Co., Ltd., (HKG: 6132) a China-based clinical-stage biotechnology company, announced its proposed initial public offering (IPO) on the Hong Kong Stock Exchange, with a global offering of 13,600,000 H shares at an offer price of HKD81.80 (USD 10.43) per share, raising approximately HK$1.11 billion (USD 142 million) in gross proceeds.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68058","og_locale":"en_US","og_type":"article","og_title":"HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies","og_description":"HJ Science Co., Ltd., (HKG: 6132) a China-based clinical-stage biotechnology company, announced its proposed initial public offering (IPO) on the Hong Kong Stock Exchange, with a global offering of 13,600,000 H shares at an offer price of HKD81.80 (USD 10.43) per share, raising approximately HK$1.11 billion (USD 142 million) in gross proceeds.","og_url":"https:\/\/flcube.com\/?p=68058","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-12T06:34:27+00:00","article_modified_time":"2026-06-12T06:34:28+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1202.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68058#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68058"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies","datePublished":"2026-06-12T06:34:27+00:00","dateModified":"2026-06-12T06:34:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68058"},"wordCount":508,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68058#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1202.webp","keywords":["HJ Science","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68058#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68058","url":"https:\/\/flcube.com\/?p=68058","name":"HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68058#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68058#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1202.webp","datePublished":"2026-06-12T06:34:27+00:00","dateModified":"2026-06-12T06:34:28+00:00","description":"HJ Science Co., Ltd., (HKG: 6132) a China-based clinical-stage biotechnology company, announced its proposed initial public offering (IPO) on the Hong Kong Stock Exchange, with a global offering of 13,600,000 H shares at an offer price of HKD81.80 (USD 10.43) per share, raising approximately HK$1.11 billion (USD 142 million) in gross proceeds.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68058#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68058"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68058#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1202.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1202.webp","width":1080,"height":608,"caption":"HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68058#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1202.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68058"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68058\/revisions"}],"predecessor-version":[{"id":68064,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68058\/revisions\/68064"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68063"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}